Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- Macaroni and cheese recall impacts more than 500,000 packages at Aldi stores
- Tokenisation poses monetary operations challenges – panel
- Strategy bought $100 million more Bitcoin but critics say MSTR shareholders now own less of it
- CFTC chair Selig defends decision to approve ‘perps’ in U.S.
- Biocon's Mazumdar Shaw Says Firm On Track To Be Top Insulin Maker
- Weakness in Crude Oil Weighs on Sugar Prices
- IMF chief says no global slowdown in sight yet, but risks are high
- Factbox-What you should know about G7 host town Evian-Les-Bains
Tuesday, June 16
